$7.58
3.07% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US2300311063
Symbol
CGEM
Sector
Industry

Cullinan Oncology Inc Stock price

$7.82
-0.18 2.25% 1M
-8.67 52.58% 6M
-4.36 35.80% YTD
-9.17 53.97% 1Y
-4.22 35.05% 3Y
-13.18 62.76% 5Y
-13.18 62.76% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.32 4.27%
ISIN
US2300311063
Symbol
CGEM
Sector
Industry

Key metrics

Market capitalization $457.57m
Enterprise Value $60.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.78
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-196.92m
Free Cash Flow (TTM) Free Cash Flow $-145.30m
Cash position $398.98m
EPS (TTM) EPS $-3.14
P/E forward negative
P/S forward 45.76
EV/Sales forward 6.07
Short interest 17.17%
Show more

Is Cullinan Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cullinan Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Cullinan Oncology Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Cullinan Oncology Inc forecast:

Buy
100%

Financial data from Cullinan Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.31 0.31
0% 0%
-
-0.31 -0.31
0% 0%
-
- Selling and Administrative Expenses 53 53
28% 28%
-
- Research and Development Expense 143 143
4% 4%
-
-197 -197
3% 3%
-
- Depreciation and Amortization 0.31 0.31
0% 0%
-
EBIT (Operating Income) EBIT -197 -197
3% 3%
-
Net Profit -167 -167
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cullinan Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cullinan Oncology Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S. Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions Ca...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.
More Cullinan Oncology Inc News

Company Profile

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Nadim Ahmed
Employees 111
Founded 2016
Website cullinantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today